No Data
RaQualia Pharma Reports 2024 Financial Results and Strategic Expansion
RaQualia Pharma: Financial results briefing materials for the fiscal year ending 2024/12
In the fiscal year ending December 2024, VIS will promote mRNA-targeted small molecule drug discovery business and the creation of its own pipeline.
Veritas In Silico <130A> announced its fiscal results for the year ending December 2024 on the 13th. Business revenue decreased by 46.0% compared to the previous year to 0.194 billion yen, with an operating loss of 0.212 billion yen (compared to a profit of 0.037 billion yen in the previous term), an ordinary loss of 0.233 billion yen (compared to a profit of 0.035 billion yen in the previous term), and a net loss of 0.236 billion yen (compared to a profit of 0.033 billion yen in the previous term). In the company's mRNA-targeted small molecule drug discovery business, the drug discovery platform ibVIS(R) is being utilized, and TORAY INDS INC <3402>.
RaQualia Pharma: Summary of financial results for the fiscal year ending 2024/12 [Japanese GAAP] (consolidated)
RaQualia Pharma Sees FY Loss Y71.00M
RaQualia Pharma FY Loss Y495.00M Vs Loss Y323.00M